Clinician vs Patient Reporting of Baseline and Postbaseline Symptoms for Adverse Event Assessment in Cancer Clinical Trials Atkinson, Thomas M. , Dueck, Amylou C. , Satele, Daniel V. ... - - JAMA Oncol - 2020 Manuscript - Secondary - Meta-Analysis - Health Outcome - N0591
Comparison Between Clinician- and Patient-Reporting of Baseline (BL) and Post-BL Symptomatic Toxicities in Cancer Cooperative Group Clinical Trials (NCCTG N0591 [Alliance]) Atkinson, Thomas M. , Satele, Daniel V. , Sloan, Jeff A. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Health Outcome - N0591
Age and the Risk of Paclitaxel‐Induced Neuropathy in Women with Early‐Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101 Barginear, Myra , Dueck, Amylou C. , Allred, Jacob B. ... - - Oncologist - 2019 Manuscript - Primary - Primary - Older Adult - A151411 , CALGB-40101 , CALGB-70301
Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - JAMA Oncol - 2017 Manuscript - Secondary-not-in-original - Meta-Analysis - Health Outcome - CALGB-30607 , CALGB-30610 , CALGB-40502 , CALGB-40503 , CALGB-40601 , CALGB-70604 , CALGB-70501 , CALGB-80405 , CALGB-90401
Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048 Basch, Ethan , Dueck, Amylou C. , Rogak, Lauren J. ... - - J. Clin. Oncol - 2018 Manuscript - Secondary-not-in-original - Primary - Health Outcome - N1048
Association between adaptive immune signature and outcome in HER2-positive breast cancer treated with trastuzumab and lapatinib in the NCCTG-N9831 (Alliance) and NeoALTTO trials Chumsri, Saranya , Serie, Daniel , Mashadi-Hossein, Afshin ... - ASCO - J Clin Oncol - 2018 Abstract - Secondary-not-in-original - Primary - GI - N9831
Perceived Risk for Cancer Progression and Psychological Status in Chronic Lymphocytic Leukemia Patients: CALGB 70603 (Alliance) Deshields, Teresa , Dueck, Amylou C. , Rogers, Kerry ... - - Leuk. Lymphoma - 2019 Manuscript - Primary - Primary - Health Outcome - CALGB-70603 , CALGB-10501
Quality of life (QOL) among patients (pts) with HER2+ breast cancer (bc) treated with adjuvant lapatinib and/or trastuzumab in the ALTTO study (BIG 2-06, Alliance N063D). Dueck, Amylou C. , Hillman, David W. , Kottschade, Lisa A. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - Breast - N063D
Validity and Reliability of the U.S. National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Dueck, Amylou C. , Mendoza, Tito R. , Mitchell, Sandra A. ... - - JAMA Oncol - 2015 Manuscript - Primary - Primary - Health Outcome - NCT02158637
A cluster-randomized study of clinician-patient shared vs standard reporting of symptomatic adverse events using PRO-CTCAE nested in a multicenter trial of multimodal therapy for rectal cancer (Alliance N1048 PROSPECT) Dueck, Amylou C. , Mitchell, S.A. , Rogak, Lauren I. , Ginos, Brenda ... - ISOQOL - Qual Life Res - 2015 Abstract - Secondary - Primary - GI - N1048
Impact of c-MYC Protein Expression on Outcome of Patients with Early-Stage HER2+ Breast Cancer Treated with Adjuvant Trastuzumab NCCTG (Alliance) N9831 Dueck, Amylou C. , Reinholz, Monica M. , Geiger, Xochiquetzal J. ... - - Clin. Cancer Res. - 2013 Manuscript - Secondary - Primary - Breast - N9831
Patient-reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in NCCTG (Alliance) N1031 (Randomized Phase II Study of Two Doses of Pixantrone in Patients with Metastatic Breast Cancer) Dueck, Amylou C. , Sideras, Kostandinos , Sloan, Jeff ... - ISOQOL - Quality of Life Research - 2013 Abstract - Secondary - Primary - Breast - N1031
Sorafenib for Advanced and Refractory Desmoid Tumors Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian A. ... - - N. Engl. J. Med. - 2018 Manuscript - Primary - Primary - Experimental - A091105
Phase III, randomized, double blind, placebo (P)-controlled trial of sorafenib (S) in desmoid tumor, (DT) (ALLIANCE A091105) Gounder, Mrinal M. , Mahoney, Michelle R. , Van Tine, Brian Andrew ... - ASCO - J Clin Oncol - 2018 Abstract - Primary - Primary - Experimental - A091105
Randomized phase II trial of capecitabine and lapatinib with or without cixutumumab in patients with HER2+ breast cancer previously treated with trastuzumab and an anthracycline and/or a taxane: NCCTG N0733 (Alliance). Haluska, Paul , Bernath, Albert M. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Breast - N0733
Radiotherapy and Adjuvant Trastuzumab in Operable Breast Cancer: Tolerability and Adverse Event Data From the NCCTG Phase III Trial N9831 Halyard, Michele Y. , Pisansky, Thomas M. , Dueck, Amylou C. ... - - J Clin Oncol - 2009 Manuscript - Secondary - Primary - Breast - N9831
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8 Kearns, Ann E. , Northfelt, Donald W. , Dueck, Amylou C. ... - - Support Care Cancer - 2010 Manuscript - Primary - Primary - Symptom Inter - N01C8
Musculoskeletal side effects over time and the association of side effects and adherence in women taking neoadjuvant letrozole for estrogen receptor positive DCIS (CALGB 40903) Kimmick, Gretchen , Dueck, Amylou C. , Shelby, Rebecca ... - SABCS - Cancer Res - 2020 Abstract - Secondary - Primary - Health Outcome - CALGB-40903
Phase III trial of gabapentin alone or in conjunction with an antidepressant in the management of hot flashes in women who have inadequate control with an antidepressant alone: NCCTG N03C5. Loprinzi, Charles L , Kugler, John W , Barton, Debra L ... - - J. Clin. Oncol. - 2007 Manuscript - Primary - Primary - Symptom Inter - N03C5
Combining Survival and Toxicity Effect Sizes from Clinical Trials: NCCTG 89-20-52 (Alliance) Major-Elechi, Brittny T. , Novotny, Paul J. , Singh, Jasvinder A. ... - - Int J Stat Med Res - 2018 Manuscript - No-Endpoint - Other - Health Outcome - NCCTG-89-20-52
How Much Missing Data is Too Much? Monte Carlo Simulations to Develop SISAQOL Guidelines for Missing Data Handling. Mazza, Gina L. , Coens, Corneel , Pe, Madeline , Dorme, Lien ... - ISOQOL - Qual Life Res - 2018 Abstract - No-Endpoint - Other - Health Outcome - N07C2
Central Pathology Laboratory Review of HER2 and ER in Early Breast Cancer: An ALTTO Trial [BIG 2-06 / NCCTG N063D (Alliance)] Ring Study McCullough, Ann E. , Dell'Orto, Patrizia , Reinholz, Monica M. ... - - Breast Cancer Res. Treat. - 2014 Manuscript - Secondary - Primary - Correl Sci NOS - N063D
The relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831 Perez, Edith A. , Baehner, Frederick L. , Butler, Steven M. ... - - Breast Cancer Res - 2015 Manuscript - Secondary - Primary - Breast - NCCTG-N9831
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J. Clin. Oncol. - 2013 Manuscript - Secondary - Primary - Breast - N9831
Predictability of Adjuvant Trastuzumab Benefit in N9831 Patients Using the ASCO/CAP HER2-Positivity Criteria Perez, Edith A. , Dueck, Amylou C. , McCullough, Ann E. ... - - J Natl Cancer Inst - 2012 Manuscript - Secondary - Primary - Breast - N9831
Disease-free survival (DFS) and treatment effect estimates of the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance]; N063D) in the adjuvant treatment of HER2-positive early breast cancer (EBC) patients according to hormone receptor status Perez, Edith A. , Holmes, Eileen , Baselga, José ... - ESMO - Ann. Oncol. - 2014 Abstract - Secondary - Primary - Breast - N063D
C-MYC Alterations and Association With Patient Outcome in Early-Stage HER2-Positive Breast Cancer From the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial Perez, Edith A. , Jenkins, Robert B. , Dueck, Amylou C. ... - - J Clin Oncol - 2011 Manuscript - Secondary - Primary - Breast - N9831
HER2 and Chromosome 17 Effect on Patient Outcome in the N9831 Adjuvant Trastuzumab Trial Perez, Edith A. , Reinholz, Monica M. , Hillman, David W. ... - - J Clin Oncol - 2010 Manuscript - Secondary - Primary - Breast - N9831
Association of genomic analysis of immune function genes and clinical outcome in the NCCTG (Alliance) N9831 adjuvant trastuzumab trial. Perez, Edith A. , Thompson, E. Aubrey , Anderson, S. Keith ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - Breast - N9831
Genomic Analysis Reveals That Immune Function Genes Are Strongly Linked to Clinical Outcome in the North Central Cancer Treatment Group N9831 Adjuvant Trastuzumab Trial Perez, Edith A. , Thompson, E. Aubrey , Ballman, Karla V. ... - - J. Clin. Oncol - 2015 Manuscript - Secondary - Primary - Breast - N9831
First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC). Piccart-Gebhart, Martine J. , Holmes, Andrew Peter , Baselga, Jose ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary - Primary - Breast - N063D
Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial Piccart-Gebhart, Martine , Holmes, Eileen , Baselga, José ... - - J. Clin. Oncol - 2016 Manuscript - Primary - Primary - Breast - N063D
Tolerability and Toxicity of Trastuzumab or Trastuzumab + Lapatinib in Older Patients Ponde, Noam Falbel , Agbor-Tarh, Dominique , Lago, Lissandra Dal ... - ASCO - JCO - 2019 Abstract - Secondary-not-in-original - Primary - Breast - N063D
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D). Pondé, Noam , Agbor-Tarh, Dominique , Dal Lago, Lissandra ... - - Breast Cancer Res. Treat. - 2020 Manuscript - Secondary-not-in-original - Primary - Breast - N063D
IGF1R Protein Expression is Not Associated with Differential Benefit to Concurrent Trastuzumab in Early-Stage HER2-positive Breast Cancer from the North Central Cancer Treatment Group (Alliance) Adjuvant Trastuzumab Trial N9831 Reinholz, Monica M. , Chen, Beiyun , Dueck, Amylou C. ... - - Clin. Cancer Res. - 2017 Manuscript - Secondary - Primary - Breast - NCCTG-N9831
Cytokeratin-19 and mammaglobin gene expression in circulating tumor cells from metastatic breast cancer patients enrolled in North Central Cancer Treatment Group (NCCTG) trials, N0234/336/436/437 Reinholz, Monica M. , Kitzmann, Kathleen A. , Tenner, Kathleen ... - - Clin. Cancer Res. - 2011 Manuscript - Secondary-not-in-original - Primary - Breast - N0336 , N0234 , N0338 , N0436 , N0437
Cost of chemotherapy for metastatic colorectal cancer with either bevacizumab or cetuximab: Economic analysis of CALGB/SWOG 80405. Schrag, Deborah , Dueck, Amylou C. , Naughton, Michelle Joy ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Secondary - Primary - Health Outcome - CALGB-70502 , CALGB-80405
North Central Cancer Treatment Group (NCCTG) N0537: Phase II Trial of VEGF-Trap in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and/or a Taxane Sideras, Kostandinos , Dueck, Amylou C. , Hobday, Timothy J. ... - - Clin. Breast Cancer - 2012 Manuscript - Primary - Primary - Breast - NCCTG-N0537
Combining survival and toxicity effect sizes from clinical trials into an interpretable, quality-adjusted survival effect size estimate of treatment efficacy. Sloan, Jeff A. , Major, Brittny , Novotny, Paul J. , Grothey, Axel ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Secondary-not-in-original - Primary - Symptom Inter - NCCTG-89-20-52
Scientific imperatives, clinical implications, and theoretical underpinnings for the investigation of the relationship between genetic variables and patient-reported quality-of-life outcomes Sprangers, Mirjam A. G. , Sloan, Jeff A. , Barsevick, Andrea ... - - Qual Life Res - 2010 Manuscript - Secondary-not-in-original - Comprehensive - Health Outcome - N9741
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in CALGB 50401 (Alliance) Thanarajasingam, Gita , Leonard, John P. , Witzig, Thomas E. ... - - Lancet Haematol - 2020 Manuscript - No-Endpoint - Other - Health Outcome - A151617 , CALGB-50401
Impact of Adjuvant Trastuzumab on Local-regional Failure Rates in the NCCTG N9831 (Alliance) Study Thorpe, Cameron S. , Vargas, Carlos E. , Dueck, Amylou C. ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019 Abstract - Secondary-not-in-original - Primary - Breast - N9831
Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. Vargas, Carlos E , Thorpe, Cameron S , Dueck, Amylou C ... - - Cancer - 2020 Manuscript - Secondary-not-in-original - Primary - Breast - N9831
Comparison of chemotherapy toxicity over time according to age and performance status in patients with advanced non-small cell lung cancer: a toxicity over time analysis of CALGB 9730 (Alliance A151729) Wong, Melisa L. , Gao, Junheng , Thanarajasingam, Gita ... - SIOG (ISOG) - J Geriatric Oncol - 2018 Abstract - Primary - Primary - Older Adult - CALGB-9730
Expanding beyond maximum grade: Chemotherapy toxicity over time by age and performance status in advanced non-small cell lung cancer in CALGB 9730 (Alliance A151729). Wong, Melisa L , Gao, Junheng , Thanarajasingam, Gita , Sloan, Jeff A ... - - Oncologist - 2020 Manuscript - Primary - Primary - Older Adult - A151729 , CALGB-9730
